230 related articles for article (PubMed ID: 17914318)
1. Efficacy of risperidone treatment in Smith-Magenis syndrome (del 17 pll. 2).
Niederhofer H
Psychiatr Danub; 2007 Sep; 19(3):189-92. PubMed ID: 17914318
[TBL] [Abstract][Full Text] [Related]
2. Sleep disturbance in Smith-Magenis syndrome (del 17 p11.2).
Smith AC; Dykens E; Greenberg F
Am J Med Genet; 1998 Mar; 81(2):186-91. PubMed ID: 9613860
[TBL] [Abstract][Full Text] [Related]
3. Dose-dependent effect of risperidone treatment in a case of 22q13.3 deletion syndrome.
Pasini A; D'Agati E; Casarelli L; Curatolo P
Brain Dev; 2010 May; 32(5):425-7. PubMed ID: 19428206
[TBL] [Abstract][Full Text] [Related]
4. [Smith-Magenis syndrome: a report of two new cases and an approximation to their characteristic behavioural phenotype].
Blanco-Barca O; Gallego-Blanco M; Ruiz-Ponte C; Barros-Angueira F; Esquete-López C; Eirís-Puñal J; Castro-Gago M
Rev Neurol; 2004 Jun 1-15; 38(11):1038-42. PubMed ID: 15202082
[TBL] [Abstract][Full Text] [Related]
5. Detection and delineation of an unusual 17p11.2 deletion by array-CGH and refinement of the Smith-Magenis syndrome minimum deletion to approximately 650 kb.
Schoumans J; Staaf J; Jönsson G; Rantala J; Zimmer KS; Borg A; Nordenskjöld M; Anderlid BM
Eur J Med Genet; 2005; 48(3):290-300. PubMed ID: 16179224
[TBL] [Abstract][Full Text] [Related]
6. Mosaicism for del(17)(p11.2p11.2) underlying the Smith-Magenis syndrome.
Juyal RC; Kuwano A; Kondo I; Zara F; Baldini A; Patel PI
Am J Med Genet; 1996 Dec; 66(2):193-6. PubMed ID: 8958329
[TBL] [Abstract][Full Text] [Related]
7. Systemic growth hormone corrects sleep disturbance in Smith-Magenis syndrome.
Itoh M; Hayashi M; Hasegawa T; Shimohira M; Kohyama J
Brain Dev; 2004 Oct; 26(7):484-6. PubMed ID: 15351087
[TBL] [Abstract][Full Text] [Related]
8. Gender, genotype, and phenotype differences in Smith-Magenis syndrome: a meta-analysis of 105 cases.
Edelman EA; Girirajan S; Finucane B; Patel PI; Lupski JR; Smith AC; Elsea SH
Clin Genet; 2007 Jun; 71(6):540-50. PubMed ID: 17539903
[TBL] [Abstract][Full Text] [Related]
9. Constitutional interstitial deletion of 17(p11.2) (Smith-Magenis syndrome): a clinically recognizable microdeletion syndrome. Report of two cases and review of the literature.
Fischer H; Oswald HP; Duba HC; Doczy L; Simma B; Utermann G; Haas OA
Klin Padiatr; 1993; 205(3):162-6. PubMed ID: 8350589
[TBL] [Abstract][Full Text] [Related]
10. Mutations in RAI1 associated with Smith-Magenis syndrome.
Slager RE; Newton TL; Vlangos CN; Finucane B; Elsea SH
Nat Genet; 2003 Apr; 33(4):466-8. PubMed ID: 12652298
[TBL] [Abstract][Full Text] [Related]
11. A physical map of the mouse shaker-2 region contains many of the genes commonly deleted in Smith-Magenis syndrome (del17p11.2p11.2).
Probst FJ; Chen KS; Zhao Q; Wang A; Friedman TB; Lupski JR; Camper SA
Genomics; 1999 Feb; 55(3):348-52. PubMed ID: 10049592
[TBL] [Abstract][Full Text] [Related]
12. Smith-Magenis syndrome in Puerto Rico: a case report.
Jardón J; Izquierdo NJ
Bol Asoc Med P R; 2009; 101(2):59-61. PubMed ID: 19954105
[TBL] [Abstract][Full Text] [Related]
13. Three young children with Smith-Magenis syndrome: their distinct, recognisable behavioural phenotype as the most important clinical symptoms.
Willekens D; De Cock P; Fryns JP
Genet Couns; 2000; 11(2):103-10. PubMed ID: 10893661
[TBL] [Abstract][Full Text] [Related]
14. Mood disorder in a patient with Smith-Magenis syndrome: a case report.
Bersani G; Russo D; Limpido L; Marconi D
Neuro Endocrinol Lett; 2007 Feb; 28(1):7-10. PubMed ID: 17277733
[TBL] [Abstract][Full Text] [Related]
15. A Turkish patient with large 17p11.2 deletion presenting with Smith Magenis syndrome.
Tug E; Cine N; Aydin H
Genet Couns; 2011; 22(1):11-9. PubMed ID: 21614983
[TBL] [Abstract][Full Text] [Related]
16. Smith-Magenis syndrome with West syndrome in a 5-year-old girl: a long-term follow-up study.
Hino-Fukuyo N; Haginoya K; Uematsu M; Nakayama T; Kikuchi A; Kure S; Kamada F; Abe Y; Arai N; Togashi N; Onuma A; Tsuchiya S
J Child Neurol; 2009 Jul; 24(7):868-73. PubMed ID: 19264735
[TBL] [Abstract][Full Text] [Related]
17. Hemizygosity for the COP9 signalosome subunit gene, SGN3, in the Smith-Magenis syndrome.
Elsea SH; Mykytyn K; Ferrell K; Coulter KL; Das P; Dubiel W; Patel PI; Metherall JE
Am J Med Genet; 1999 Dec; 87(4):342-8. PubMed ID: 10588842
[TBL] [Abstract][Full Text] [Related]
18. Smith-Magenis syndrome.
Elsea SH; Girirajan S
Eur J Hum Genet; 2008 Apr; 16(4):412-21. PubMed ID: 18231123
[TBL] [Abstract][Full Text] [Related]
19. An individual with Gilles de la Tourette syndrome and Smith-Magenis microdeletion syndrome: is chromosome 17p11.2 a candidate region for Tourette syndrome putative susceptibility genes?
Shelley BP; Robertson MM; Turk J
J Intellect Disabil Res; 2007 Aug; 51(Pt 8):620-4. PubMed ID: 17598875
[TBL] [Abstract][Full Text] [Related]
20. Neurologic and developmental features of the Smith-Magenis syndrome (del 17p11.2).
Gropman AL; Duncan WC; Smith AC
Pediatr Neurol; 2006 May; 34(5):337-50. PubMed ID: 16647992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
